| Bakary Marong, DNP ARNP AGACNP-BC | |
|
11120 Ne 33rd Pl Ste 202, Bellevue, WA 98004-1444 | |
| (206) 823-1004 | |
| Not Available |
| Full Name | Bakary Marong |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner - Acute Care |
| Location | 11120 Ne 33rd Pl Ste 202, Bellevue, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073187159 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2100X | Nurse Practitioner - Acute Care | AP61142494 (Washington) | Primary |
| Entity Name | Comprehensive Postacute Care Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023525698 PECOS PAC ID: 2567723133 Enrollment ID: O20180221002756 |
News Archive
Influenza strikes five to 15 percent of the population and is estimated to cost the U.S. economy a hefty $90 million per year. If researchers can improve the understanding of how environmental conditions affect the ability of the influenza virus to survive and infect others while it is airborne, they may be able to help improve prediction and control of its spread.
Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
DigiPath Labs of Las Vegas, a subsidiary of DigiPath, Inc., has entered into a one-year agreement with Euphoria Wellness to conduct comprehensive safety and potency tests on the products Euphoria will sell in its Las Vegas medical marijuana dispensary.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite controversy surrounding bone morphogenetic proteins (BMPs) in the US, they will be introduced into South Korea over the next year and experience double-digit growth in Australia, driving the Asia Pacific bone graft substitute market through 2013.
› Verified 1 days ago
| Entity Name | Daiya Healthcare Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477027381 PECOS PAC ID: 6002158615 Enrollment ID: O20190501001702 |
News Archive
Influenza strikes five to 15 percent of the population and is estimated to cost the U.S. economy a hefty $90 million per year. If researchers can improve the understanding of how environmental conditions affect the ability of the influenza virus to survive and infect others while it is airborne, they may be able to help improve prediction and control of its spread.
Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
DigiPath Labs of Las Vegas, a subsidiary of DigiPath, Inc., has entered into a one-year agreement with Euphoria Wellness to conduct comprehensive safety and potency tests on the products Euphoria will sell in its Las Vegas medical marijuana dispensary.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite controversy surrounding bone morphogenetic proteins (BMPs) in the US, they will be introduced into South Korea over the next year and experience double-digit growth in Australia, driving the Asia Pacific bone graft substitute market through 2013.
› Verified 1 days ago
| Entity Name | Signify Health Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750845863 PECOS PAC ID: 2163764424 Enrollment ID: O20191230002111 |
News Archive
Influenza strikes five to 15 percent of the population and is estimated to cost the U.S. economy a hefty $90 million per year. If researchers can improve the understanding of how environmental conditions affect the ability of the influenza virus to survive and infect others while it is airborne, they may be able to help improve prediction and control of its spread.
Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
DigiPath Labs of Las Vegas, a subsidiary of DigiPath, Inc., has entered into a one-year agreement with Euphoria Wellness to conduct comprehensive safety and potency tests on the products Euphoria will sell in its Las Vegas medical marijuana dispensary.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite controversy surrounding bone morphogenetic proteins (BMPs) in the US, they will be introduced into South Korea over the next year and experience double-digit growth in Australia, driving the Asia Pacific bone graft substitute market through 2013.
› Verified 1 days ago
| Entity Name | Highcare Medical Consultants Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801677760 PECOS PAC ID: 4284083072 Enrollment ID: O20231205002336 |
News Archive
Influenza strikes five to 15 percent of the population and is estimated to cost the U.S. economy a hefty $90 million per year. If researchers can improve the understanding of how environmental conditions affect the ability of the influenza virus to survive and infect others while it is airborne, they may be able to help improve prediction and control of its spread.
Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
DigiPath Labs of Las Vegas, a subsidiary of DigiPath, Inc., has entered into a one-year agreement with Euphoria Wellness to conduct comprehensive safety and potency tests on the products Euphoria will sell in its Las Vegas medical marijuana dispensary.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite controversy surrounding bone morphogenetic proteins (BMPs) in the US, they will be introduced into South Korea over the next year and experience double-digit growth in Australia, driving the Asia Pacific bone graft substitute market through 2013.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bakary Marong, DNP ARNP AGACNP-BC 12433 Admiralty Way Apt Q403, Everett, WA 98204-7570 Ph: (425) 268-7279 | Bakary Marong, DNP ARNP AGACNP-BC 11120 Ne 33rd Pl Ste 202, Bellevue, WA 98004-1444 Ph: (206) 823-1004 |
News Archive
Influenza strikes five to 15 percent of the population and is estimated to cost the U.S. economy a hefty $90 million per year. If researchers can improve the understanding of how environmental conditions affect the ability of the influenza virus to survive and infect others while it is airborne, they may be able to help improve prediction and control of its spread.
Molecular Detection Inc., a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced the first close of a new financing. The financing was led by MentorTech Ventures II, LP and included Robin Hood Ventures, Elm Spring Holdings and the Mid-Atlantic Angel Group Fund I and II, LP, all existing investors. The company raised $1.4 million as part of a follow-on to its $3.3 million Series C round announced in late 2009.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
DigiPath Labs of Las Vegas, a subsidiary of DigiPath, Inc., has entered into a one-year agreement with Euphoria Wellness to conduct comprehensive safety and potency tests on the products Euphoria will sell in its Las Vegas medical marijuana dispensary.
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, despite controversy surrounding bone morphogenetic proteins (BMPs) in the US, they will be introduced into South Korea over the next year and experience double-digit growth in Australia, driving the Asia Pacific bone graft substitute market through 2013.
› Verified 1 days ago
Ms. Jessica Swenson, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1231 116th Ave Ne, Suite 950, Bellevue, WA 98004 Phone: 425-454-3366 Fax: 425-460-5954 | |
Mrs. Kara Harrington Brennan, MSN, ARNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 11522 Ne 20th St, Bellevue, WA 98004 Phone: 425-462-2531 Fax: 425-454-6176 | |
Dr. Ambera Dedic, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1231 116th Ave Ne Ste 400, Bellevue, WA 98004 Phone: 425-289-3199 | |
Keenan Smith, PMHNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2105 112th Ave Ne Ste 201, Bellevue, WA 98004 Phone: 425-968-5948 | |
Leslie Elaine Smith, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1600 116th Ave Ne, Suite #102, Bellevue, WA 98004 Phone: 425-454-5311 Fax: 425-454-8188 | |
Hana K Ryan, AGPCNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 11695 Ne 4th St, Bellevue, WA 98004 Phone: 425-637-1855 Fax: 425-344-7970 | |
Thomas Chan, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 15585 Ne 24th St, Bellevue, WA 98007 Phone: 888-227-3312 |